Bogdan Mocanu
Research Subjects
Research Interests
Bogdan Mocanu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anca Daniela Stanescu
Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
1 shared publication - Andreea Nicoleta Marinescu
Faculty of Medicine, University of Medicine and Pharmacy “Carol-Davila”, 020021 Bucharest, Romania
1 shared publication - Beatrice Anghel
Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
1 shared publication - Crenguta Serboiu
Histology and Molecular Biology Department, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
1 shared publication - Cătălin Aliuș
General Surgery Department, Emergency University Hospital Bucharest, 050098 Bucharest, Romania
1 shared publication - Dragos Eugen Georgescu
Department of Surgery, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania
1 shared publication
Latest Publications
- Open Access
- 5 March 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (5) , 547
Optimizing Palliative Pelvic Radiotherapy in Gynecological Cancers: A Systematic Review and Analysis
Background: Palliative radiotherapy plays a crucial role in managing symptomatic gynecological cancers (GCs). This article aims to systematically review literature studies on palliative pelvic radiotherapy in cervical, endometrial, ovarian, vaginal, and vulvar cancers. The primary focus is centered around evaluating symptom relief, quality of life (QOL), and toxicity in order to ascertain optimal radiotherapy regimens. Methodology: For this thorough review, we mainly relied on Medline to gather papers published until November 2023. Selected studies specifically detailed symptomatology and QOL responses in palliative pelvic radiotherapy used for GCs. Results: Thirty-one studies, mostly retrospective studies and those lacking standardized outcome measures, showed varied responses. Encouraging outcomes were noted in managing hemorrhage (55%) and pain control (70%). However, comprehensively assessing overall symptom response rates and toxicity remained challenging. Investigations into 10 Gy fractionation revealed benefits in addressing tumor-related bleeding and pain in female genital tract cancers. Conclusions: Palliative pelvic radiotherapy effectively manages symptomatic GCs. Nonetheless, unresolved dosing and fractionation considerations warrant further investigation. Embracing modern therapies alongside radiotherapy offers improved symptom control, emphasizing the importance of selecting suitable patients for successful GC palliation interventions.
- 5 March 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (5) , 547
Open AccessOptimizing Palliative Pelvic Radiotherapy in Gynecological Cancers: A Systematic Review and Analysis
Background: Palliative radiotherapy plays a crucial role in managing symptomatic gynecological cancers (GCs). This article aims to systematically review literature studies on palliative pelvic radiotherapy in cervical, endometrial, ovarian, vaginal, and vulvar cancers. The primary focus is centered around evaluating symptom relief, quality of life (QOL), and toxicity in order to ascertain optimal radiotherapy regimens. Methodology: For this thorough review, we mainly relied on Medline to gather papers published until November 2023. Selected studies specifically detailed symptomatology and QOL responses in palliative pelvic radiotherapy used for GCs. Results: Thirty-one studies, mostly retrospective studies and those lacking standardized outcome measures, showed varied responses. Encouraging outcomes were noted in managing hemorrhage (55%) and pain control (70%). However, comprehensively assessing overall symptom response rates and toxicity remained challenging. Investigations into 10 Gy fractionation revealed benefits in addressing tumor-related bleeding and pain in female genital tract cancers. Conclusions: Palliative pelvic radiotherapy effectively manages symptomatic GCs. Nonetheless, unresolved dosing and fractionation considerations warrant further investigation. Embracing modern therapies alongside radiotherapy offers improved symptom control, emphasizing the importance of selecting suitable patients for successful GC palliation interventions.